All Stories

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'

Leap Therapeutics is laying off half of its staff as it narrows the focus of its lead cancer drug against the backdrop of a “difficult market environment," its CEO explained.

May 13, 2025 - 14:48
 0
Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'
Leap Therapeutics is laying off half of its staff as it narrows the focus of its lead cancer drug against the backdrop of a “difficult market environment," its CEO explained.
Read More

Tags:

Previous Article

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos t...

Next Article

STAT+: UnitedHealth stock tumbles as CEO resigns, 2025 outlook pulled

Related Posts

Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership

Korro lays off 20% of staff to fund genetic med trials,...

May 8, 2025  0

Beacon's rare eye disease gene therapy signals vision function improvements in early phase 2 data

Beacon's rare eye disease gene therapy signals vision f...

May 8, 2025  0

GE HealthCare rolls out new AI-equipped SPECT/CT nuclear medicine scanner

GE HealthCare rolls out new AI-equipped SPECT/CT nuclea...

May 8, 2025  0